Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Price and Volume

Volume	0
Open	8.680
Bid (Size)	8.680 (100)
Ask (Size)	8.800 (114)
Prev. Close	8.680
Today's Range	8.680 - 8.680
52wk Range	8.680 - 8.680
Shares Outstanding	59,762,106
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sage (SAGE) Q2 Revenue Jumps 264% ↗

August 01, 2025

Via The Motley Fool

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

July 31, 2025

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to...

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

More News

Sage Therapeutics Announces Second Quarter 2025 Financial Results

July 30, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

July 28, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

July 25, 2025

From Biogen Inc.

Via GlobeNewswire

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Via Investor's Business Daily

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock ↗

July 08, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders

July 05, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

June 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

From FN Media Group LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders

June 25, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

Via FinancialNewsMedia

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗

June 22, 2025

Via Stocktwits

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗

June 17, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders

June 17, 2025

From Halper Sadeh LLC

Via GlobeNewswire

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News ↗

June 17, 2025

Via Benzinga

June 17, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

June 17, 2025

Via Benzinga

US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert ↗

June 17, 2025

Via Benzinga

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone ↗

June 17, 2025

Via Benzinga

Monday's session: top gainers and losers ↗

June 16, 2025

Via Chartmill

S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June ↗

June 16, 2025

Via Benzinga

Frequently Asked Questions

Is Sage Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sage Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sage Therapeutics, Inc. - Common Stock trade on?

Sage Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sage Therapeutics, Inc. - Common Stock?

The ticker symbol for Sage Therapeutics, Inc. - Common Stock is SAGE on the Nasdaq Stock Market

What is the current price of Sage Therapeutics, Inc. - Common Stock?

The current price of Sage Therapeutics, Inc. - Common Stock is 8.680

When was Sage Therapeutics, Inc. - Common Stock last traded?

The last trade of Sage Therapeutics, Inc. - Common Stock was at 07/30/25 04:00 PM ET

What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?

The market capitalization of Sage Therapeutics, Inc. - Common Stock is 518.74M

How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?

Sage Therapeutics, Inc. - Common Stock has 519M shares outstanding.